Dr. Bryan Schneider is a medical oncologist and professor of medicine and medical/molecular genetics at the IU Melvin and Bren Simon Cancer Center and the Vera Bradley Chair of Oncology. He is also co-leader of the IU Grand Challenge Precision Health Initiative triple negative breast cancer research team, working to discover targeted treatments.
Schneider’s research has identified several biomarkers that predict which patients may suffer severe side effects from chemotherapy, before it is administered. His work has also led to the discovery of disproportionate therapy-induced toxicities in African American patients. He has published over 70 research articles in high-impact medical journals.
Areas of Expertise
Hematology/oncology, triple negative breast cancer, precision genomics, precision medicine, IU Grand Challenge Precision Health, breast cancer disparities.